Meeting
2019 ASCO Annual Meeting
Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.
Authors
Jinani Jayasekera
Lombardi Cancer Center MedStar Georgetown University Hospital, Washington, DC
Jinani Jayasekera , Clyde B. Schechter , Joseph A. Sparano , Claudine Isaacs , Robert James Gray , Christopher Cadham , Jeanne S. Mandelblatt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 526)
DOI
10.1200/JCO.2019.37.15_suppl.526
Abstract #
526
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2016 ASCO Annual Meeting
Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.
First Author: Carlos Hernando Barcenas
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
Poster
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
First Author: Adam Brufsky